[go: up one dir, main page]

MA30814B1 - Nouvelles compositions en depot injectables et leur procede de fabrication - Google Patents

Nouvelles compositions en depot injectables et leur procede de fabrication

Info

Publication number
MA30814B1
MA30814B1 MA31821A MA31821A MA30814B1 MA 30814 B1 MA30814 B1 MA 30814B1 MA 31821 A MA31821 A MA 31821A MA 31821 A MA31821 A MA 31821A MA 30814 B1 MA30814 B1 MA 30814B1
Authority
MA
Morocco
Prior art keywords
manufacture
novel injectable
deposition compositions
deposition
compositions
Prior art date
Application number
MA31821A
Other languages
English (en)
Inventor
Rajesh Jain
Kour Chand Jindal
Sampath Kumar Devarajan
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MA30814B1 publication Critical patent/MA30814B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

NOUVELLES COMPOSITIONS EN DÉPÔT INJECTABLES COMPRENANT AU MOINS UN PRINCIPE ACTIF AVEC ÉVENTUELLEMENT UN OU DES EXCIPIENTS DE QUALITÉ PHARMACEUTIQUE, SE PRÉSENTANT SOUS LA FORME D'UN SYSTÈME MULTI-COMPOSANT QUI, LORS DE L'ADMINISTRATION À UN SUJET QUI EN A BESOIN, FORME IN SITU UN DÉPÔT OU UN IMPLANT EN GEL AU POINT D'INJECTION AU MOMENT DU CONTACT AVEC DES LIQUIDES ORGANIQUES. SONT ÉGALEMENT DÉCRITS UN PROCÉDÉ DE FABRICATION DE TELLES COMPOSITION ET LEUR MÉTHODE D'UTILISATION.
MA31821A 2006-10-05 2009-04-27 Nouvelles compositions en depot injectables et leur procede de fabrication MA30814B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2195DE2006 2006-10-05

Publications (1)

Publication Number Publication Date
MA30814B1 true MA30814B1 (fr) 2009-10-01

Family

ID=39268891

Family Applications (2)

Application Number Title Priority Date Filing Date
MA31824A MA30817B1 (fr) 2006-10-05 2009-04-27 Nouvelles compositions en depot injectables et leur procede de fabrication.
MA31821A MA30814B1 (fr) 2006-10-05 2009-04-27 Nouvelles compositions en depot injectables et leur procede de fabrication

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA31824A MA30817B1 (fr) 2006-10-05 2009-04-27 Nouvelles compositions en depot injectables et leur procede de fabrication.

Country Status (17)

Country Link
US (2) US20100015195A1 (fr)
EP (2) EP2089000A2 (fr)
JP (2) JP2010505821A (fr)
KR (2) KR20090094811A (fr)
CN (2) CN101541313A (fr)
AR (1) AR063120A1 (fr)
AU (2) AU2007303794A1 (fr)
BR (2) BRPI0720346A2 (fr)
CA (2) CA2665101A1 (fr)
CL (1) CL2007002851A1 (fr)
EA (1) EA200970348A1 (fr)
IL (2) IL197946A0 (fr)
MA (2) MA30817B1 (fr)
MX (2) MX2009003737A (fr)
RU (1) RU2009116933A (fr)
TN (2) TN2009000124A1 (fr)
WO (2) WO2008041245A2 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
DK2526996T3 (da) 2002-12-20 2019-12-02 Xeris Pharmaceuticals Inc Formulering til intrakutan injektion
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
NZ581560A (en) * 2007-06-25 2011-09-30 Otsuka Pharma Co Ltd Microspheres having core/shell structure containing aripiprazole
AR070033A1 (es) * 2007-11-06 2010-03-10 Panacea Biotec Ltd Composiciones inyectables, sus procesos y usos
CA2726861C (fr) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
US9180088B2 (en) 2008-03-07 2015-11-10 Scidose, Llc Fulvestrant formulations
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
CN101569622B (zh) * 2008-04-30 2012-11-21 天津药物研究院 一种用于注射给药的药物制剂及其制备方法
EA014044B1 (ru) * 2008-07-09 2010-08-30 Общество С Ограниченной Ответственностью "Аква-Альянс" Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты)
DK2341905T4 (da) * 2008-09-04 2023-12-11 Amylin Pharmaceuticals Llc Depotformuleringer med ikke-vandige bærere
EP2379059A4 (fr) 2008-12-10 2012-10-31 Anhui Zhongren Technology Co Ltd Composition à libération contrôlée
WO2010093945A2 (fr) 2009-02-13 2010-08-19 Glaukos Corporation Implant médicamenteux uvéoscléral et ses procédés d'implantation
US8673264B2 (en) * 2009-03-02 2014-03-18 Assistance Publique-Hopitaux De Paris Injectable biomaterial
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP3785683B1 (fr) 2009-05-18 2023-11-01 Dose Medical Corporation Implant oculaire à élution de médicament
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
CN101669942A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 难溶性药物组合物
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
RU2548753C2 (ru) 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
MX343499B (es) * 2010-03-15 2016-11-08 Ipsen Pharma Sas Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.
CN103068371A (zh) 2010-03-29 2013-04-24 赢创有限公司 用于在局部给药位点改进药物组合物的滞留的组合物和方法
ES2390439B1 (es) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
BR112012028368B8 (pt) * 2010-08-24 2022-07-12 Otsuka Pharma Co Ltd Processo para prevenção de aglomeração de partículas de ingrediente ativo em uma suspensão, suspensão e composição de torta contendo derivado carbo estirila e óleo de silicone e/ou derivado de óleo de silicone
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
BR112013010190B1 (pt) * 2010-10-28 2019-12-31 Aequus Pharmaceuticals Inc composição farmacêutica
EP2654715B1 (fr) 2010-11-24 2017-01-25 Dose Medical Corporation Implant oculaire à élution de médicament
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2683364B1 (fr) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Formulations stables pour injection parentérale de médicaments peptidiques
AU2012231160B2 (en) * 2011-03-18 2017-04-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EA027744B1 (ru) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Лекарственные формы для лечения сахарного диабета
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
EP2705835A1 (fr) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
CN103483353B (zh) * 2012-06-13 2016-02-24 上海现代药物制剂工程研究中心有限公司 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
WO2014179615A2 (fr) * 2013-05-01 2014-11-06 Dae Won Park Copolymères biodégradables, systèmes comprenant les copolymères et leurs procédés de formation et d'utilisation
US20160200891A1 (en) * 2013-08-22 2016-07-14 Polyvalor Limited Partnership Porous gels and methods for their preparation
JP2015093854A (ja) * 2013-11-12 2015-05-18 株式会社クレハ 水性組成物および加水分解抑制方法
CH708890B1 (de) * 2013-11-22 2018-03-15 Sandel Thomas Ball, vorzugsweise Golfball, sowie ein mit dem Ball kommunizierbares elektronisches Gerät.
US20150174254A1 (en) * 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2015184173A1 (fr) 2014-05-29 2015-12-03 Dose Medical Corporation Implants à caractéristiques de libération contrôlée de médicament et leurs procédés d'utilisation
US11129940B2 (en) 2014-08-06 2021-09-28 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3218485A1 (fr) * 2014-11-10 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Compositions pharmaceutiques à action prolongée contre l'hépatite c
EP3028721A1 (fr) * 2014-12-05 2016-06-08 Exchange Imaging Technologies GmbH Formulation de nano-structures avec caractéristique inverse de gélification pour injection
KR101692314B1 (ko) * 2015-03-27 2017-01-03 주식회사 주빅 지용성 약물의 생분해성 고분자 내 용해 시스템: 스마트 폴리머 시스템
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2017040853A1 (fr) 2015-09-02 2017-03-09 Glaukos Corporation Implants d'administration de médicament présentant capacité d'administration bidirectionnelle
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2017083717A1 (fr) * 2015-11-11 2017-05-18 Qrono, Inc. Compositions pharmaceutiques à libération prolongée et méthodes d'utilisation
WO2017105512A1 (fr) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations et procédés de commande du cycle de reproduction et de l'ovulation
WO2017184881A1 (fr) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Dispositif d'administration de médicament oculaire biorésorbable
US20190282588A1 (en) * 2016-05-16 2019-09-19 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018015915A1 (fr) * 2016-07-22 2018-01-25 Cadila Healthcare Limited Composition à libération parentérale contrôlée d'un antipsychotique atypique.
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
JP2020514408A (ja) * 2017-01-23 2020-05-21 サビオール ライフテック コーポレーションＳａｖｉｏｒ Ｌｉｆｅｔｅｃ Ｃｏｒｐｏｒａｔｉｏｎ 有効成分微粒子の製造
CN106822039A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 水难溶或微溶性药物缓释组合物及其制备方法
CN106822042A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 一种利培酮缓释组合物及其制备方法
CN106822043A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 利培酮缓释组合物及其制备方法
CN106727422B (zh) * 2017-03-09 2018-10-02 王秋玉 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
TWI793165B (zh) 2017-09-11 2023-02-21 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
BR112020004978A2 (pt) 2017-09-15 2020-09-15 Oxular Limited composição farmacológica liofilizada estéril, formulação farmacêutica, forma farmacêutica unitária, kit, método para o tratamento de uma doença ou afecção, método para o tratamento de uma doença ou afecção ocular e composição farmacológica, composição farmacológica para uso
KR102496504B1 (ko) * 2018-03-23 2023-02-06 라보라뚜아르 마조르 남성 피임을 위한 비호르몬 조성물 및 방법
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
EP3833318A4 (fr) * 2018-08-10 2022-05-11 Ephemeral Solutions, Inc. Particules contenant des agents colorants et procédés pour les utiliser
EP3988139A4 (fr) * 2019-06-21 2023-07-19 Korea University Research and Business Foundation Agent gonflant in vivo, injection comprenant celui-ci, et son procédé de préparation
US12201591B2 (en) 2019-07-03 2025-01-21 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN111388744B (zh) * 2020-01-15 2021-05-18 华中科技大学 一种凝胶贮库及其制法与制备术后止血制剂的应用
KR20230052921A (ko) * 2020-08-17 2023-04-20 휴먼웰 파마슈티컬 유에스 지속성 인-시투(in-situ) 형성/겔화 조성물
CN111956599B (zh) * 2020-09-29 2023-02-17 江苏集萃新型药物制剂技术研究所有限公司 皮下植入药剂及其组合物和制备方法
KR102266384B1 (ko) * 2021-01-25 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
KR102652905B1 (ko) * 2021-08-09 2024-04-01 주식회사 메디폴리머 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
WO2023233051A1 (fr) 2022-05-18 2023-12-07 Laboratorios Farmacéuticos Rovi, S.A. Compositions injectables à libération prolongée destinées à être utilisées dans le cadre du traitement par rispéridone en association avec des inhibiteurs de l'enzyme cyp2d6
WO2024151625A1 (fr) * 2023-01-10 2024-07-18 Georgetown University Compositions de plga non toxiques et leurs procédés de fabrication et d'utilisation
CN116850146B (zh) * 2023-05-22 2024-05-14 济南大学 伏硫西汀自由碱或其药用盐长效缓释制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
ATE188375T1 (de) * 1992-11-17 2000-01-15 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
CA2435415A1 (fr) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticules de polymere biodegradable encapsulant une substance biologiquement active et formulations pharmaceutiques a liberation prolongee contenant lesdites particules
CA2463358C (fr) * 2001-10-10 2012-03-13 Pierre Fabre Medicament Microspheres biodegradables a liberation prolongee et leur procede de preparation
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms

Also Published As

Publication number Publication date
KR20090087441A (ko) 2009-08-17
KR20090094811A (ko) 2009-09-08
EA200970348A1 (ru) 2009-10-30
JP2010505821A (ja) 2010-02-25
EP2089000A2 (fr) 2009-08-19
EP2086505A2 (fr) 2009-08-12
WO2008041246A2 (fr) 2008-04-10
CN101541316A (zh) 2009-09-23
MA30817B1 (fr) 2009-10-01
MX2009003737A (es) 2009-06-16
JP2010505819A (ja) 2010-02-25
CL2007002851A1 (es) 2008-01-18
TN2009000125A1 (en) 2010-10-18
US20100098735A1 (en) 2010-04-22
US20100015195A1 (en) 2010-01-21
MX2009003735A (es) 2009-04-22
RU2009116933A (ru) 2010-11-10
IL197946A0 (en) 2009-12-24
CA2665105A1 (fr) 2008-04-10
AU2007303794A1 (en) 2008-04-10
CA2665101A1 (fr) 2008-04-10
CN101541313A (zh) 2009-09-23
AU2007303793A1 (en) 2008-04-10
BRPI0720346A2 (pt) 2014-06-24
IL197947A0 (en) 2009-12-24
WO2008041245A3 (fr) 2008-05-22
WO2008041246A3 (fr) 2008-05-29
WO2008041245A2 (fr) 2008-04-10
TN2009000124A1 (en) 2010-10-18
AR063120A1 (es) 2008-12-30
BRPI0718288A2 (pt) 2013-11-19

Similar Documents

Publication Publication Date Title
MA30814B1 (fr) Nouvelles compositions en depot injectables et leur procede de fabrication
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
ATE534732T1 (de) Molekulare targets und zusammensetzungen sowie verfahren zu deren identifikation zur behandlung von degenerations- und entzündungserkankungen
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
EP2727605A4 (fr) Analogue d'exendine-4 pégylé par du polyéthylène glycol ou un dérivé de celui-ci, son procédé de préparation et composition pharmaceutique pour prévenir ou traiter le diabète, le contenant en tant que principe actif
EP4009400A4 (fr) Matériau actif d'anode composite, son procédé de préparation et anode le comprenant
EA200700566A1 (ru) Фармацевтические композиции, включающие леветирацетам, и способы их получения
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
UY27990A1 (es) Derivados de pirrolidona como inhibidores de maob
EP2346899A4 (fr) Anticorps à pénétration cellulaire, spécifique de séquence et hydrolysant les acides nucléiques, son procédé de préparation et composition pharmaceutique le contenant
MA28342A1 (fr) Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AR054252A1 (es) Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina
MX2022011544A (es) Metodo para me]orar la estabilidad de una composición farmaceutica que comprende un medicamento de alta penetración y la compsoición farmaceutica obtenida de el.
EP1571155A4 (fr) Peptides et compositions medicinales contenant ces peptides
EP1905823A4 (fr) Levure composite adaptée à la fermentation d'alcool en concentration élevée
WO2006010084A3 (fr) Systeme pour introduire des agents therapeutiques dans des cellules vivantes et noyaux de cellule
FR2851734B1 (fr) Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
DE602004017214D1 (de) Antibakterielle und/oder gegen protozoen wirksame nitroimidazolderivatverbindungen mit ureasehemmender wirkung, verfahren zur herstellung dieser verbindungen und deren verwendung in pharmazeutischen zusammensetzungen und medikamenten
EP3763735A4 (fr) Procédé de préparation d'un biomatériau ayant une tyrosine fonctionnalisée de manière sélective, biomatériau ayant une tyrosine fonctionnalisée de manière sélective, et composition pharmaceutique le contenant en tant que principe actif
DE602006010111D1 (de) Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure
ATE419838T1 (de) Pharmazeutische zubereitungsform von aliphatischen amin-polymeren und verfahren zu deren herstellung
DE60220953D1 (de) Pharmazeutische zusammensetzungen enthaltend eine antihistaminische abschwellende arzneistoffkombination und ein verfahren zur herstellung davon
Finkel Drugs, Labor, and Colonial Expansion
Khiali et al. Efficacy and Safety of SGLT2 Inhibitors in Individuals with Sold Organ Transplantation: A Systematic Review and Meta-analysis